Form 4: Health Catalyst CFO Jason Alger Sells Shares Under 10b5-1 Trading Plan

Health Catalyst's CFO, Jason Alger, sold 2,899 shares of common stock at a price of $7.3911 per share on September 6, 2024, under a pre-arranged trading plan.

Summary

• On September 6, 2024, Jason Alger, the Chief Financial Officer of Health Catalyst, Inc. (HCAT), sold 2,899 shares of the company's common stock.
• The sale was executed at a price of $7.3911 per share.
• Following the transaction, Alger directly owns 114,106 shares of Health Catalyst common stock.
• The sale was conducted under a pre-arranged trading plan adopted on March 13, 2024, in accordance with Rule 10b5-1.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan, indicating it was likely for personal financial planning rather than a reflection of the CFO's view on the company's prospects.

Industry Context

Insider sales are a common occurrence, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. The market typically views sales by insiders with caution, but the existence of a 10b5-1 plan mitigates some of the negative sentiment.

Stakeholder Impact

• The sale of shares by a high-ranking officer could create uncertainty among shareholders, although the 10b5-1 plan helps to alleviate concerns about insider trading.

Key Dates